Mental Health Disorders Among Hidradenitis Suppurativa Patients – A Review of Literature
DOI:
https://doi.org/10.12775/QS.2025.40.59407Keywords
hidradenitis suppurativa, mental health, depression, anxiety, schizophrenia, bipolar, suicide, drug abuseAbstract
Introduction and objective: Hidradenitis suppurativa (HS) is a chronic skin condition that primarily affects areas of the body with a high concentration of sweat glands, characterised by painful papules, abscesses and scarring. It occurs in approximately 1-4% of people and is frequently associated with other health problems such as obesity, smoking and metabolic problems. HS can cause both physical and psychological suffering beyond simple pain. This review aims to assess the mental health challenges of people living with HS.
Review methods: All data were collected from publicly available sources. This article's databases were accessed via PubMed, Scopus, and Web of Science.
A brief description of the state of knowledge: HS is more than a dermatological disorder; it’s intimately associated with multiple other conditions. Patients affected by HS have a greater prevalence of depression, anxiety, and other mental health disorders. The psychological toll of HS is significant, with research indicating elevated rates of conditions such as bipolar disorder, schizophrenia and substance abuse. The association between physical health and mental well-being is an important concern, as these mental health challenges can lead to the further decline in a patient’s quality of life and increase the risk of self-harm or suicide.
Summary: Overall, although HS is primarily a physical health issue, its psychological implications must not be overlooked. People are increasingly prone to depression, anxiety and other mental health issues. These psychological issues can be a vicious cycle of suffering that impacts their general wellbeing. Treating both the somatic and mental implications of HS must be a priority for enhancing patient outcomes.
References
1. Caccavale S, Tancredi V, Boccellino MP, Babino G, Fulgione E, Argenziano G. Hidradenitis Suppurativa Burdens on Mental Health: A Literature Review of Associated Psychiatric Disorders and Their Pathogenesis. Life (Basel). 2023;13(1).
2. Ballard K, Shuman VL. Hidradenitis Suppurativa. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
3. Huilaja L, Tiri H, Jokelainen J, Timonen M, Tasanen K. Patients with Hidradenitis Suppurativa Have a High Psychiatric Disease Burden: Finnish Nationwide Registry Study. Journal of Investigative Dermatology. 2018;138(1):46-51.
4. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhasz I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-44.
5. Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S27-35.
6. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J, Quality of Life Group of the French Society of D. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621-3.
7. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.
8. Shojaei D, Liu C, Lam J. The presentation of anxiety and depression among children and youth diagnosed with hidradenitis suppurativa: A review. Pediatr Dermatol. 2023;40(6):983-9.
9. Markota Cagalj A, Marinovic B, Bukvic Mokos Z. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci. 2022;23(7).
10. Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000Res. 2018;7:1930.
11. Vossen A, van der Zee HH, Prens EP. Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Front Immunol. 2018;9:2965.
12. Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):999-1010.
13. Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50-61.
14. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-58.
15. de Oliveira A, Bloise G, Moltrasio C, Coelho A, Agrelli A, Moura R, et al. Transcriptome Meta-Analysis Confirms the Hidradenitis Suppurativa Pathogenic Triad: Upregulated Inflammation, Altered Epithelial Organization, and Dysregulated Metabolic Signaling. Biomolecules. 2022;12(10).
16. Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91(3):328-32.
17. Tugnoli S, Agnoli C, Silvestri A, Giari S, Bettoli V, Caracciolo S. Anger, Emotional Fragility, Self-esteem, and Psychiatric Comorbidity in Patients with Hidradenitis Suppurativa/Acne Inversa. J Clin Psychol Med Settings. 2020;27(3):527-40.
18. Matusiak L. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171-e7.
19. Gooderham M, Papp K. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S19-22.
20. Jackson-Cowan L, Cole EF, Arbiser JL, Silverberg JI, Lawley LP. TH2 sensitization in the skin-gut-brain axis: How early-life Th2-mediated inflammation may negatively perpetuate developmental and psychologic abnormalities. Pediatr Dermatol. 2021;38(5):1032-9.
21. Misitzis A, Goldust M, Jafferany M, Lotti T. Psychiatric comorbidities in patients with hidradenitis suppurativa. Dermatol Ther. 2020;33(4):e13541.
22. Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27(4):473-8.
23. Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29(2):371-6.
24. Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97-103.
25. Rymaszewska JE, Krajewski PK, Szczech J, Szepietowski JC. Depression and anxiety in hidradenitis suppurativa patients: a cross-sectional study among Polish patients. Postepy Dermatol Alergol. 2023;40(1):35-9.
26. Machado MO, Stergiopoulos V, Maes M, Kurdyak PA, Lin PY, Wang LJ, et al. Depression and Anxiety in Adults With Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(8):939-45.
27. Patel KR, Lee HH, Rastogi S, Vakharia PP, Hua T, Chhiba K, et al. Association between hidradenitis suppurativa, depression, anxiety, and suicidality: A systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(3):737-44.
28. Jalenques I, Ciortianu L, Pereira B, D'Incan M, Lauron S, Rondepierre F. The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: Systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(2):542-53.
29. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161(4):831-9.
30. Tzur Bitan D, Berzin D, Cohen A. Hidradenitis Suppurativa and Bipolar Disorders: A Population-Based Study. Dermatology. 2020;236(4):298-304.
31. Queissner R, Pilz R, Dalkner N, Birner A, Bengesser SA, Platzer M, et al. The relationship between inflammatory state and quantity of affective episodes in bipolar disorder. Psychoneuroendocrinology. 2018;90:61-7.
32. Fond G. Inflammation in psychiatric disorders. European Psychiatry. 2014;29(S3):551-2.
33. Tzur Bitan D, Berzin D, Cohen AD. Hidradenitis suppurativa and schizophrenia: a nationwide cohort study. J Eur Acad Dermatol Venereol. 2020;34(3):574-9.
34. Poot F. Psychiatric diseases from the psychotic spectrum in hidradenitis suppurativa patients: An under-recognized comorbidity. J Eur Acad Dermatol Venereol. 2020;34(3):442-3.
35. Vekic DA, Cains GD. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 2. Australas J Dermatol. 2018;59(4):261-6.
36. Mebazaa A, Ben Hadid R, Cheikh Rouhou R, Trojjet S, El Euch D, Mokni M, et al. Hidradenitis suppurativa: a disease with male predominance in Tunisia. Acta Dermatovenerol Alp Pannonica Adriat. 2009;18(4):165-72.
37. Torrent C, Amann B, Sanchez-Moreno J, Colom F, Reinares M, Comes M, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118(1):4-18.
38. Kromann CB, Ibler KS, Kristiansen VB, Jemec GB. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94(5):553-7.
39. McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE, Jr., Leverich GS, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63(3):207-13.
40. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry. 2007;68(11):1793-8.
41. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
42. Phan K, Huo YR, Smith SD. Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis. Ann Transl Med. 2020;8(13):821.
43. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. Psychol Med. 2003;33(3):395-405.
44. Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased Suicide Risk in Patients with Hidradenitis Suppurativa. J Invest Dermatol. 2018;138(1):52-7.
45. Tiri H, Huilaja L, Jokelainen J, Timonen M, Tasanen K. Women with Hidradenitis Suppurativa Have an Elevated Risk of Suicide. J Invest Dermatol. 2018;138(12):2672-4.
46. Ortiz-Alvarez J, Hernandez-Rodriguez JC, Duran-Romero AJ, Conejo-Mir Sanchez J, Pereyra-Rodriguez JJ, Osorio-Gomez GF. Hidradenitis suppurativa and suicide risk: a multivariate analysis in a disease with a high psychological burden. Arch Dermatol Res. 2023;315(3):637-42.
47. Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-91.
48. Andersen PL, Nielsen RM, Sigsgaard V, Jemec GBE, Riis PT. Body Image Quality of Life in Patients with Hidradenitis Suppurativa Compared with Other Dermatological Disorders. Acta Derm Venereol. 2020;100(8):adv00107.
49. Matusiak L, Szczech J, Kaaz K, Lelonek E, Szepietowski JC. Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa. Acta Derm Venereol. 2018;98(2):191-4.
50. Garg A, Papagermanos V, Midura M, Strunk A, Merson J. Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: A population-based analysis in the United States. J Am Acad Dermatol. 2018;79(3):495-500 e1.
51. Kimball AB, Sundaram M, Banderas B, Foley C, Shields AL. Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. J Dermatolog Treat. 2018;29(2):152-64.
52. Horvath B, Janse IC, Sibbald GR. Pain management in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S47-51.
53. Puza CJ, Wolfe SA, Jaleel T. Pain Management in Patients With Hidradenitis Suppurativa Requiring Surgery. Dermatol Surg. 2019;45(10):1327-30.
54. Theut Riis P, Pedersen OB, Sigsgaard V, Erikstrup C, Paarup HM, Nielsen KR, et al. Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study. Br J Dermatol. 2019;180(4):774-81.
55. Lesort C, Villani AP, Giai J, Becherel PA, Delaunay J, Fattouh K, et al. High prevalence of cannabis use among patients with hidradenitis suppurativa: results from the VERADDICT survey. Br J Dermatol. 2019;181(4):839-41.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Alicja Tabian, Lidia Mądrzak, Bartłomiej Roszkowski, Magdalena Pałdyna, Ewelina Biało-Wójcicka

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 83
Number of citations: 0